Delimiting MOGAD as a disease entity using translational imaging

Front Neurol. 2023 Dec 7:14:1216477. doi: 10.3389/fneur.2023.1216477. eCollection 2023.

Abstract

The first formal consensus diagnostic criteria for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) were recently proposed. Yet, the distinction of MOGAD-defining characteristics from characteristics of its important differential diagnoses such as multiple sclerosis (MS) and aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder (NMOSD) is still obstructed. In preclinical research, MOG antibody-based animal models were used for decades to derive knowledge about MS. In clinical research, people with MOGAD have been combined into cohorts with other diagnoses. Thus, it remains unclear to which extent the generated knowledge is specifically applicable to MOGAD. Translational research can contribute to identifying MOGAD characteristic features by establishing imaging methods and outcome parameters on proven pathophysiological grounds. This article reviews suitable animal models for translational MOGAD research and the current state and prospect of translational imaging in MOGAD.

Keywords: EAE; animal models; imaging; myelin oligodendrocyte glycoprotein associated disease; translational research.

Publication types

  • Review

Grants and funding

We thank the Sumaira Foundation for supporting this article collection.